Patent · US Active

1-(cyclopent-2-en-1-yl)-3-(2-hydroxy-3-(arylsulfonyl)phenyl)urea derivatives as CXCR2 inhibitors

US10336719B2 · kind B2 · utility

0Cited by

0References

15Claims

0Family size

Assignee

GlaxoSmithKline Intellectual Property Development Limited · GB

Inventors

Weichun Chen · Zhejiang, CN
Ebere F Igboko · Shanghai, CN
Xichen Lin · Shanghai, CN
Hongfu Lu · Shanghai, CN
Feng Ren · Shanghai, CN
Paul Bryan Wren · Uxbridge, GB
Zhongmiao Xu · Shanghai, CN
Ting Yang · Shanghai, CN
Lindong Zhu · Shanghai, CN

Key dates

Filing date	Sep 13, 2018
Grant date	Jul 2, 2019
Priority date	—
Expiry date	Sep 13, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07C2601/14
WIPO fieldOrganic fine chemistry
WIPO sectorChemistry

Abstract

The invention relates to 1-(3-sulfonylphenyl)-3-(cyclopent-2-en-1-yl)urea derivatives, and their use in treating or preventing diseases and conditions mediated by the CXCR2 receptor. In addition, the invention relates to compositions containing the derivatives and processes for their preparation.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.